Curr Hepat Rep. 2011 March; 10(1): 33–40.
Published online 2010 December 24. doi: 10.1007/s11901-010-0078-7. PMCID: PMC3030745
Management of Hepatitis C Antiviral Therapy Adverse Effects
Hubert Sung,1 Michael Chang,2 and Sammy Saab1,2,3 -1Department of Surgery, University of California at Los Angeles, Los Angeles, CA USA ,2Department of Medicine, University of California at Los Angeles, Los Angeles, CA USA ,3Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095 USA
Hepatitis C is one of the leading causes of liver disease in the United States, affecting more than 4 million individuals. The current treatment regimen involves pegylated interferon in combination with ribavirin. Although antiviral treatment has been associated with a greater than 50% sustained viral response rate, the adverse effects have proven to be detrimental to quality of life and therapy adherence, and consequently lead to lower sustained viral response rates. This article identifies the most frequently described complications associated with pegylated interferon and ribavirin. The active management of these complications is discussed, including both preventive and empiric treatments.
Keywords: Hepatitis C virus, Pegylated interferon, Ribavirin, Side effects, Management
Hepatitis C is a major public health concern. With almost 4 million Americans with chronic infection, hepatitis C is the one of the leading causes of chronic liver disease and is the single most common indication for liver transplantation [1–3]. Antiviral therapy is effective in more than half of infected patients, but the actual rate of sustained viral response depends on viral, host, and adherence factors. Viral and host factors tend to be nonmodifiable, whereas interventions may increase adherence.
The current standard of care for hepatitis C therapy is the combination of pegylated interferon and ribavirin . Sustained viral response for antiviral therapy is about 55% [5•, 6•]. However, adverse effects from antiviral therapy directly affect treatment adherence and can decrease the likelihood of a sustained viral response. These complications can severely compromise quality of life . Both interferon and ribavirin are associated with signature effects that are predictable, manageable, and improve with dose modification or discontinuation [8••]. Rarely is an adverse effect from hepatitis C antiviral therapy permanent. Adverse effects can arise from both interferon and ribavirin, and may lead to treatment termination and dose modifications in 10% to 15% and 32% to 42% of patients, respectively [5•, 6•, 9]. When interferon and ribavirin doses are reduced by a certain threshold, the sustained viral response may also decrease . For instance, the results of a recent study by Reddy et al. [11••] demonstrated the sustained viral response is 34% when a patient’s cumulative ribavirin dose decreases below 60%.
An understanding of the antiviral adverse effects is essential to effectively deal with adverse effects in a timely manner. The goal during therapy is to maximize the likelihood of achieving a sustained viral response while improving tolerability and maintaining quality of life. Providers should discuss the potential issues with patients and with their social support. During clinic follow-up, patients should be queried about treatment adverse effects. Many times, the adverse effects can accumulate over time and lead to early treatment discontinuation. The current paper reviews the most frequent adverse effects associated with hepatitis C therapy, and proposes interventions to ameliorate complications. The adverse effects from pegylated interferon and ribavirin are considered separately.
The efficacy and therapeutic value of hepatitis C treatment is dependent on the degree of tolerability and adherence to the drugs, which in turn are related to the management of the side effects. The frequency and number of side effects related to interferon therapy are common, with most clinical trials reporting at least one interferon-related adverse effect in 95% of the patient group [5•, 10, 12]. The most frequently reported adverse effects from interferon include constitutional, hematologic, neuropsychiatric, and endocrinologic complications See; (Table 1). The onset of the adverse effects differ. The onset can be from minutes after the interferon injection, to months See; (Table 2).
The most common adverse effects from interferon are constitutional symptoms. The severity of these side effects is inversely related to the amount of time after the interferon injection. Fatigue, headache, and fever were each reported in about 50% to 60% of treated patients [6•, 9, 12].
Constitutional effects can manifest early during therapy, even after the first dose of interferon . However, several constitutional effects (e.g., fever) resolve or wane after the first several injections. Certain precautions can assist with the effects, such as maintaining adequate hydration and light to moderate exercise. The suggested intake of water in ounces is equivalent to half the patient’s body weight in pounds. To prevent interferon therapy from interfering with work, injections should occur on Fridays. As a result, most of the constitutional effects will occur on Saturday. By Monday, treated patients tend to feel better. The use of acetaminophen or ibuprofen before the injection can also ameliorate many of the constitutional adverse effects. Other adverse effects (e.g., arthralgia) can respond to acetaminophen or ibuprofen. However, ibuprofen should be avoided in patients with liver cirrhosis.
Hematologic side effects are the most recurrent abnormal laboratory values that can lead to dosage reductions and premature treatment termination . Because of its myelosuppressive effect, interferon can affect hemoglobin, white blood cell, and platelet values. However, the anemia seen during combination treatment is mostly associated with ribavirin-induced hemolytic anemia.
The definition of neutropenia varies between the two commercially available pegylated interferons. For instance, neutropenia is defined as an absolute neutrophil count less than 500 cells/mm3 when using pegylated interferon α-2a, and below 750 cells/mm3 when using pegylated interferon α-2b [13, 14]. Certain populations appear to be more likely affected by the neutropenic effects of interferon, such as the elderly and non-African Americans . Although African Americans are prone to constitutional neutropenia, initiation of interferon treatment usually only leads to minimal further decreases in neutrophil count. However, the clinical impact of neutropenia on significant infection is controversial. In a study of 119 subjects, 22 infections were documented and were dominated by sinusitis, pharyngitis, and urinary tract infections .
In most clinical trials, neutropenia is treated with dose modification. Interferon dose reduction occurs in about 17% to 20% of patients and treatment termination in 2% to 3% of patients [16••, 17, 18]. The rapid decline in neutrophils usually occurs within the first 2 weeks of treatment initiation, with stabilization occurring over the next 4–6 weeks . One study of 25 patients illustrated a median drop of 21% in neutrophils following the first dose of interferon .
Another option for patients who develop neutropenia from interferon therapy is the use of granulocyte colony-stimulating factor (GCSF) [20–22]. Few clinical studies have included the use of GCSF [20, 21]. These studies have indicated that the GCSF is able to raise neutrophil counts during interferon therapy. However, the results of a recent study failed to show a correlation between interferon-induced neutropenia and incidence or severity of infections . Thus, although GCSF can improve neutrophil counts, future studies are required to determine the utility of GCSF in clinical practice, particularly given its increased costs and its own associated adverse effects. Regardless of the intervention of neutropenia, affected patients need regular cell counts to monitor neutrophil levels.
Another interferon-induced hematologic adverse effect is thrombocytopenia. Several mechanisms exist for the development of thrombocytopenia. It has been shown that platelet count can fall up to 50% because of posttranscriptional suppression of megakaryopoiesis or platelet sequestration in capillaries . In addition, there have been rare cases of immune-mediated thrombocytopenia leading to significant decreases in platelet count, which can be rectified by termination of interferon treatment or corticosteroid therapy [24, 25]. Platelet reduction often occurs within the first 24 h of interferon administration, with nadir being reached within 8 weeks of therapy. Platelet levels will then stabilize at this low level during the length of therapy [23, 24]. However, it may compound the already present thrombocytopenia associated with cirrhosis and portal hypertension. With pegylated interferon α-2a, dose reduction is suggested when platelet counts fall below 50,000/mL and therapy termination when counts fall below 25,000/mL . The threshold is set a little higher with respect to pegylated interferon α-2b, with limits of 80,000/mL for dose reduction and 50,000/mL for discontinuation . Discontinuation of therapy is often followed by normalization of platelet counts within 4–8 weeks [23, 24]. Recent studies have shown eltrombopag, a thrombopoietin receptor agonist, to effectively increase platelet counts to greater than 250,000/mm3 in thrombocytopenic patients with hepatitis C virus . However, its safety and utility in patients with advanced liver disease remains to be determined, because it may increase the risk of thrombosis .
Not only is the prevalence of depression in patients with hepatitis C higher than the general population, antiviral therapy increases the likelihood of a variety of neuropsychiatric complications, including worsening depression, anxiety, and suicidal ideation . Thus, it is imperative to assess for underlying depression and other preexisting psychiatric illness before considering antiviral therapy. In fact, antiviral therapy is contraindicated in patients with uncontrolled neuropsychiatric disorders. With a treated patient’s approval, it is helpful for their social support to provide feedback on mood changes because patients themselves may not notice changes in their disposition.
About 20% to 30% of patients treated with interferons report depression during therapy or the exacerbation of a preexisting depressive state [6•, 29]. Depending on the type and severity of neuropsychiatric effects, patients may be monitored or may be treated with more frequent clinic visits or telephone calls, antidepressant medications, psychiatric referral, or dose modification or even discontinuation.
The selection of antidepressant medication requires tailoring, because depression may have nuances that improve or worsen with the choice of therapy . The greatest experience with antidepressant medications is with selective serotonin reuptake inhibitors (SSRIs) [31, 32]. Although the use of antidepressant medication may not necessarily significantly improve the likelihood of a sustained viral response, it does improve adherence and help maintain quality of life . In patients believed at increased risk of interferon-associated depression, preemptive treatment with SSRIs was associated with a significant reduction in the incidence of major depression .
Thyroid abnormalities are the most commonly associated interferon-induced endocrinologic adverse effect, occurring in 1% to 6% of interferon-treated patients [34, 35]. Both hypo- and hyperthyroidism can develop. Patients with hepatitis C may be predisposed to developing thyroid abnormalities because of an increased rate of thyroid autoantibodies prior to starting antiviral therapy . For instance, one study described the development of thyroid disorder in 60% of patients with antithyroid microsome antibodies present prior to the initiation of interferon therapy, compared to only 3.3% of patients without these antibodies . In a similar study, 38.5% of females with antithyroid peroxidase antibodies developed hypothyroidism versus only 7.8% of females lacking these antibodies .
Thyroid function tests should be obtained at baseline and every 12 weeks during antiviral treatment, and after treatment completion. If a patient develops symptomatic hypothyroidism, hormone replacement should be initiated while continuing antiviral therapy. Moreover, if the patient develops hyperthyroidism, the patient should be referred to an endocrinologist for further management with reevaluation of the antiviral regimen. Similar to the autoantibody destruction seen in the thyroid, antibodies to the adrenal cortex, pancreatic islet cells, and antiphospholipid antibodies have been reported with the use of interferon [38, 39]. Although rare, new-onset insulin-dependent diabetes mellitus with the presence of antibodies directed toward islet cells and insulin has been reported .
Many dermatologic adverse effects are associated with interferons, with an incidence ranging from 13% to 87% [5•, 41]. Besides nonspecific symptoms, reactions at the site of interferon injection are common, with 30% to 40% of patients complaining of erythema, pruritus, and tenderness [6•, 42]. Because the lesions may take weeks to resolve, it is recommended to rotate between unique injection sites. After injection, the sites are often warm and raised, expanding to a circumference of 5 cm or more. If the site continues to enlarge and remains warm and tender, the patient must be examined for possible abscess formation. Rarely, infection and skin necrosis are seen at the injection site. However, these symptoms do not necessarily warrant termination of treatment.
An additional major complaint from interferon therapy is skin dryness, which occurs in two of three treated patients . Skin dryness can be exacerbated in cold weather, and may be accompanied by intense pruritus. Topical steroids, emollients, and soothing baths may help to alleviate these symptoms, but studies have not shown a significant response . Another typical adverse effect seen with interferons is alopecia, occurring in about one third of patients, with a higher prevalence in females . To combat alopecia, the patient can cut his/her hair short prior to interferon initiation and avoid pulling, braiding, or vigorously combing the hair. In addition, patients should avoid the use of harsh hair-care products, harsh hair dyes, hair dryers, and other products that may be detrimental to hair growth.
Neurologic, pulmonary, and ophthalmologic adverse effects associated with interferon use have been reported. Sensory and autonomic neuropathies, as well as Bell’s palsy, have been documented with interferon use, most likely arising from an autoimmune phenomenon or neuronal injury caused by interferon stimulation of the immune system . Neuropathy usually resolves with the termination of interferon treatment, but additional steroids and/or cyclophosphamide may be beneficial . In addition to the neuropathies stated, there have been rare cases of myasthenia gravis. In such cases, interferon therapy is withdrawn and pyridostigmine therapy is initiated . During interferon treatment, multiple pulmonary adverse effects can occur, such as interstitial pneumonitis, alveolar disease, and sarcoidosis reactivation. If a patient complains of continual cough and dyspnea on exertion or rest, a chest radiograph should be obtained to exclude pneumonitis. Possible bacterial pneumonia should be treated with proper antibiotics in conjunction with halting antiviral therapy, which can be reinitiated when there is clinical improvement. Occasionally, pulmonary function tests may be indicated, including forced vital capacity, forced expiratory volume, and carbon monoxide diffusion capacity, as well as a thoracic CT scan. Interferon-induced interstitial pneumonitis can be life-threatening, although it usually resolves with withdrawal of interferon. However, the most common cause for cough and shortness of breath is likely ribavirin-induced .
In addition to the pulmonary and neurologic effects, interferons have been associated with retinopathy (e.g., retinal hemorrhages and cotton wool spots), particularly in patients with diabetes . In one study of 63 patients treated with antiviral therapy, 40% of patients developed retinal hemorrhages and 44% developed cotton wool spots . Diabetes and hypertension were risk factors for retinopathy [47, 49]. It is important for patients with pre-treatment risk factors for retinopathy to undergo retinal examination prior to treatment, and if any visual changes occur during treatment, to undergo ocular re-evaluation. Antiviral treatment must be halted if retinopathy worsens during therapy.
Ribavirin is used with interferon to treat hepatitis C. Like interferon, it is associated with several adverse effects. Although the adverse effects from ribavirin appear to be less severe than those from interferon, maintaining ribavirin dose appears more critical to the likelihood of achieving a sustained viral response than sustaining the interferon dose [6•]. Thus, it is still imperative to understand and be able to manage ribavirin-associated complications.
The signature adverse effect of ribavirin is anemia, occurring in up to 30% of treated individuals [5•, 6•]. Ribavirin-related anemia is one the most common reasons for dosage reduction or discontinuation of the drug, resulting in 9% to 22% of patients requiring dosage reduction [5•, 6•]. Anemia can result in persistent fatigue, shortness of breath, and lower quality-of-life scores . Treatment with ribavirin displays a drop in hemoglobin during the first 4 weeks of treatment, followed by stabilization, then normalization after treatment completion . The mechanism of ribavirin-associated hemolytic anemia is unclear, but is believed to be related to impaired antioxidant defenses and red blood cell oxidative damages through its metabolites . The degree of hemolytic anemia is directly related to ribavirin dose, renal function, and perhaps patient age [52, 53]. Recently, ITPA gene variants have been found to be protective of anemia in patients treated with ribavirin [54••].
The definition of anemia can vary. Although anemia may be suggested by the rate of hemoglobin drop, it is commonly defined by an absolute value of less than 10 g/dL . Intervention for ribavirin-induced anemia depends on the rate of hemoglobin decrease, absolute hemoglobin value, comorbidities, and symptoms. Therapeutic options include frequent monitoring, blood transfusion, erythropoietin grown factor, and ribavirin dose modification [6•, 8••, 50••]. The risk of significant anemia can be predicted by hemoglobin trends. For instance, a decrease in hemoglobin of at least of 1.5 g/dL after 2 weeks predicts significant decreases after 4 weeks of therapy . Recognition of impending anemia may prompt small reductions of ribavirin to avoid significant decline in hemoglobin.
There is a discrepancy between the intervention for anemia according to package inserts, and what is often done in clinical practice. The respective package inserts recommend decreasing the ribavirin dose by 200 mg/day when using peginterferon α-2b/ribavirin and by 600 mg/day when using peginterferon α-2a/ribavirin, if hemoglobin decreases to less than 10 g/dL in a patient without cardiac risk factors [13, 14, 55]. The package inserts also recommend termination of ribavirin if the hemoglobin levels decrease below 8.5 g/dL.
Studies have shown erythropoietin can improve hemoglobin values, maintain ribavirin dosage levels, and improve quality of life in patients with symptomatic ribavirin-induced anemia . Despite improved adherence with erythropoietin, no studies have shown that the use of erythropoietin translates to higher sustained viral response. This may be due to the large cohort of treated patients needed to show a beneficial effect. There have been reported cases of antibody-mediated pure red-cell aplasia induced by erythropoietin, which is potentially life-threatening, but resolves with termination of erythropoietin treatment and initiation of danazol . A recent study highlighted the correlation between the magnitude of hemoglobin decline and the likelihood of sustained viral response, and indicated an association between the magnitude of hemoglobin decline and ribavirin exposure . Erythropoietin use in early-onset anemia minimized treatment discontinuation and led to higher sustained viral response rates. However, erythropoietin for anemia after 8 weeks of therapy was not associated with higher sustained viral response rates. Moreover, erythropoietin has been linked to a greater incidence of mortality with its use in ischemic stroke patients . These recent concerns regarding raised risks of thromboembolic events and aplastic anemia with erythropoietin justify the judicious use of this agent.
Other ribavirin-associated complications include nausea and pulmonary, dermatologic, and teratogenic effects. Studies have shown that 25% to 40% of patients complain of nausea [5•, 6•, 12]. However, this symptom can be managed with alterations in the patient’s dietary regimen. More specifically, along with maintaining adequate hydration, patients should avoid acidic, spicy, sweet, or greasy foods. Instead, dietary intake should consist of clear beverages and dry foods (e.g., toast and crackers). If nausea persists after dietary changes, antiemetics may be prescribed.
Ribavirin therapy is often associated with a dry, nonproductive cough, which resolves only upon termination of treatment. Most patients can tolerate this adverse effect, and thus it is not a major cause of dose reductions or treatment termination. However, if the cough becomes productive or other clinical indications are present, a chest radiograph should be considered.
The addition of ribavirin in combination therapy increases the incidence of dermatologic adverse effects. More specifically, one study compared the incidence of skin rash in two groups, one receiving interferon monotherapy and one receiving interferon and ribavirin. Monotherapy resulted in an 8% incidence, whereas combination therapy resulted in 28% incidence . Dermatologic side effects with combination therapy are typified by generalized pruritus, skin xerosis, and eczematiform lesions, which are localized to the extremities. Although ribavirin is shown to increase the incidence of dermatologic conditions when added to interferon treatment, it should be noted that ribavirin alone may cause rash and pruritus. Ribavirin must be discontinued if an acute hypersensitivity reaction develops. However, transient rashes do not require ribavirin treatment interruption . Management entails topical corticosteroids, which may be tapered once signs of inflammation and irritation begin to recede. Preventive measures can be taken, with daily emollient therapy and skin moisturizers to commonly affected areas.
Ribavirin has been associated with significant teratogenic or embryocidal effects in nonhuman animal species exposed to it; therefore, patients must take proper precautions when beginning ribavirin treatment. Moreover, ribavirin therapy, which according to the Food and Drug Administration is pregnancy category X, is contraindicated in pregnant woman and in the male partners of women who are pregnant. It is imperative for patients to avoid pregnancy during ribavirin treatment and for 6 months after treatment completion. It is suggested that two reliable forms of effective contraception be used during this time. Upon cessation of treatment, recovery from ribavirin-induced testicular toxicity was apparent within one or two spermatogenesis cycles. Although human studies are lacking, there is a ribavirin pregnancy registry that enrolls pregnant women who have been directly or indirectly exposed to ribavirin . Although underpowered, the results of a recent registry questioned the association between ribavirin and human teratogenicity .
References ConclusionsThe current standard of care for the treatment of hepatitis C infection involves the use of pegylated interferon and ribavirin. This antiviral combination therapy is associated with several potentially serious adverse effects. Fortunately, pegylated interferon and ribavirin have been available for almost a decade, and most of the adverse effects regarding incidence and time of onset have been defined. The management of these antiviral complications has also been well described, including preventive and empiric strategies. Understanding the limitations of current treatment is essential to assure quality of life and adherence during therapy, and may provide insight to deal with the finer points of future treatment strategies.
AcknowledgmentsDisclosure Conflicts of interest: H. Sung—none; M. Chang—none; S. Saab—consultancy, grants, speakers’ honoraria, and travel reimbursement from Bristol-Myers Squibb, Gilead, Three Rivers, Genentech, Merck, Bayer, and Onyx, and stock/stock options in Gilead, Vertex, and Zymogenetics.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
1. National Digestive Disease Information Clearinghouse (NDDIC) Chronic Hepatitis C: Current Disease Management. Available at http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/chronichepc.pdf. Accessed August 2010.
2. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol. 2008;22(6):991–1008. doi: 10.1016/j.bpg.2008.11.002. [PubMed] [Cross Ref]
3. Armstrong GL, Wasley A, Simard EP. The Prevalence of Hepatitis C Virus Infection in the United States, 1992–2002. Ann Intern Med. 2006;144:705–14. [PubMed]
4. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74. doi: 10.1002/hep.22759. [PubMed] [Cross Ref]
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82. doi: 10.1056/NEJMoa020047. [PubMed] [Cross Ref]
6. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. doi: 10.1016/S0140-6736(01)06102-5. [PubMed] [Cross Ref]
7. Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009;16(9):605–11. doi: 10.1111/j.1365-2893.2009.01154.x. [PubMed] [Cross Ref]
8. Chak E, Saab S. Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response. Curr Hepat Rep. 2010;9(3):147–154. doi: 10.1007/s11901-010-0047-1. [PMC free article] [PubMed] [Cross Ref]
9. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 Suppl 1):S237–44. doi: 10.1002/hep.1840360730. [PubMed] [Cross Ref]
10. McHutchinson JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–9. doi: 10.1053/gast.2002.35950. [PubMed] [Cross Ref]
11. Reddy KR, Nelson DR, Zeusem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009;50(2):402–11. doi: 10.1016/j.jhep.2008.11.006. [PubMed] [Cross Ref]
12. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711–9. doi: 10.1016/S0016-5085(03)00394-9. [PubMed] [Cross Ref]
13. Pegasys [package insert]. Nutley, NJ: Hoffman-La Roche Inc. 2008.
14. PegIntron [package inset]. Kenilworth, NJ: Schering-Plough Corp. 2009.
15. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36:1273–1279. doi: 10.1053/jhep.2002.36502. [PubMed] [Cross Ref]
16. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection. 2008;36(3):250–5. doi: 10.1007/s15010-007-7132-6. [PubMed] [Cross Ref]
17. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med. 2004;140:346–355. [PubMed]
18. Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of a 2-dose regimens of peg interferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol. 2004;99:1298–305. doi: 10.1111/j.1572-0241.2004.30306.x. [PubMed] [Cross Ref]
19. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated inteferon-alpha. Gastroenterology. 2002;123:141–151. doi: 10.1053/gast.2002.34175. [PubMed] [Cross Ref]
20. Fukuda A, Kobayashi H, Teramura K, et al. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther. 2000;6:149–154. [PubMed]
21. Carreno V, Martin J, Pardo M, et al. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol. 1998;28:382–389. doi: 10.1016/S0168-8278(98)80310-3. [PubMed] [Cross Ref]
22. Sharvadze L, Karchava M, Bolokadze N, et al. Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections with hepatitis C. Georgian Med News. 2009;175:32–5. [PubMed]
23. Yamane A, Nakamura T, Suzuki H, et al. Interferon-alpha- 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood. 2008;112:542–50. doi: 10.1182/blood-2007-12-125906. [PubMed] [Cross Ref]
24. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2002;97:2040–2045. doi: 10.1111/j.1572-0241.2002.05845.x. [PubMed] [Cross Ref]
25. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alph-interferon therapy. J Hepatol. 1996;25:972–5. doi: 10.1016/S0168-8278(96)80304-7. [PubMed] [Cross Ref]
26. McHutchinson JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227–36. doi: 10.1056/NEJMoa073255. [PubMed] [Cross Ref]
27. Danish FA, Koul SS, Subhani FR, et al. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol. 2010;16(1):51–6. doi: 10.4103/1319-3767.58772. [PMC free article] [PubMed] [Cross Ref]
28. Al-Huthail YR. Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review. Saudi J Gastroenterol. 2006;12(2):59–67. doi: 10.4103/1319-3767.27847. [PubMed] [Cross Ref]
29. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patient with chronic hepatitis C. Gen Hosp Psychiatry. 2004;26:237–40. doi: 10.1016/j.genhosppsych.2004.01.003. [PubMed] [Cross Ref]
30. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry. 2009;54(9):614–25. [PubMed]
31. Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind placebo-controlled study. Gut. 2008;57:531–6. doi: 10.1136/gut.2007.131607. [PubMed] [Cross Ref]
32. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942–947. doi: 10.1038/sj.mp.4001119. [PubMed] [Cross Ref]
33. Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42:793–798. doi: 10.1016/j.jhep.2005.01.020. [PubMed] [Cross Ref]
34. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun. 2010;34(3):J322–6. doi: 10.1016/j.jaut.2009.11.008. [PubMed] [Cross Ref]
35. Marazuela M, Garca-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocinol. 1996;44:635–42. doi: 10.1046/j.1365-2265.1996.751768.x. [Cross Ref]
36. Doi F, Kakizaki S, Takagi H, et al. Long-term outcome of interferon-alpha induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2006;25(2):242–6. doi: 10.1111/j.1478-3231.2005.01089.x. [PubMed] [Cross Ref]
37. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interderon-alpha therapy for chonic hepatitis C. Am J. Gastrolenterol. 1994;89:399–403.
38. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut. 2001;48:378–383. doi: 10.1136/gut.48.3.378. [PMC free article] [PubMed] [Cross Ref]
39. Betterle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000;23:1177–1181. doi: 10.2337/diacare.23.8.1177. [PubMed] [Cross Ref]
40. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998;28:514–517. doi: 10.1016/S0168-8278(98)80328-0. [PubMed] [Cross Ref]
41. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485–92. doi: 10.1056/NEJM199811193392101. [PubMed] [Cross Ref]
42. Lubbe J, Kerl K, Negro F, et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153:1088–90. doi: 10.1111/j.1365-2133.2005.06931.x. [PubMed] [Cross Ref]
43. Aspinall RJ, Pockros PJ. Review article: the management of side-effects during therapy for hepatitis C. Aliment Pharmacol Ther. 2004;20:917–929. doi: 10.1111/j.1365-2036.2004.02192.x. [PubMed] [Cross Ref]
44. Lang AM, Norland AM, Schuneman RL. Localized interferon alfa-2b-induced alopecia. Arch Dermatol. 1999;135:1126–8. doi: 10.1001/archderm.135.9.1126. [PubMed] [Cross Ref]
45. Stubgen JP. Interferon alpha and neuromuscular disorders. K Neuroimmunol. 2009;207:3–17. doi: 10.1016/j.jneuroim.2008.12.008. [Cross Ref]
46. Weegink CJ, Chamuleau RA, Reesink HW, et al. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. J Gastroenterol. 2001;36:723–4. doi: 10.1007/s005350170038. [PubMed] [Cross Ref]
47. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol. 2001;85:1171–1173. doi: 10.1136/bjo.85.10.1171. [PMC free article] [PubMed] [Cross Ref]
48. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol. 1996;91:309–313. [PubMed]
49. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol. 1995;79:150–152. doi: 10.1136/bjo.79.2.150. [PMC free article] [PubMed] [Cross Ref]
50. McHutchison JG, Manns MP, Brown RS, Jr, et al. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol. 2007;102(4):880–9. doi: 10.1111/j.1572-0241.2007.01139.x. [PubMed] [Cross Ref]
51. DeFranceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitic C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997–1004. doi: 10.1053/he.2000.5789. [PubMed] [Cross Ref]
52. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl. 2007;13(7):1032–8. doi: 10.1002/lt.21184. [PubMed] [Cross Ref]
53. Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19:1312–7. doi: 10.1111/j.1440-1746.2004.03459.x. [PubMed] [Cross Ref]
54. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464:405–8. doi: 10.1038/nature08825. [PubMed] [Cross Ref]
55. Ribavirin [package insert]. South San Francisco, CA: Hoffman-La Roche Inc. 2010.
56. Reau N, Hadziyannis SJ, Messinger D, et al. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103(8):1981–8. doi: 10.1111/j.1572-0241.2008.01957.x. [PMC free article] [PubMed] [Cross Ref]
57. Dieterich DT, Prockros P, Schiff ER, et al.: Interim results of a randomized, double-blind placebo-controlled study demonstrates that epoietin-alfa (PROCRIT) allows maintenance of ribavirin dosing. Hepatology 2002;493.
58. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol. 2005;100:1415–9. doi: 10.1111/j.1572-0241.2005.41910.x. [PubMed] [Cross Ref]
59. Sulkwski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139(5):1602–11. doi: 10.1053/j.gastro.2010.07.059. [PubMed] [Cross Ref]
60. Jia L, Chopp M, Zhang L, et al. Erythropoietin in combination of tissue plasminogenactivator exacerbates brain hemorrhage when treatment is initiated 6 h after stroke. Stroke. 2010;41(9):2071–6. doi: 10.1161/STROKEAHA.110.586198. [PubMed] [Cross Ref]
61. Ribavirin Pregnancy Registry. Available at http://ribavirinpregnancyregistry.com/. Accessed September 2010.
62. Roberts SS, Miller RK, Jones JK, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003–2009. Birth Defects Res A Clin Mol Teratol. 2010;88:551–9. doi: 10.1002/bdra.20682. [PubMed] [Cross Ref]
Curr Hepat Rep. 2011 March; 10(1): 33–40.
Stay Updated: Get Updates For HCV New Drugs Delivered By Email
HCV In The News
Hepatitis C New Drug Research And Liver Health
RSS Feed: Website Updates
Sovaldi (Sofosbuvir) Is Now FDA Approved
Hepatitis C- Gilead's Sovaldi (Sofosbuvir) Is Now FDA Approved
Gilead’s Sovaldi™ (Sofosbuvir)
U.S. Patient Assistance Program Gilead is committed to ensuring that people with hepatitis C can access Sovaldi and has launched Support Path™ (www.MySupportPath.com) to provide assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine
Gilead said Friday it would price the drug at $84,000 for one 12-week supply. Patients with a less common subtype of the disease may need to take the drug for 24 weeks, raising the cost to $168,000 for one course of treatment. Drugs already on the market run between $25,000 and $50,000 for a course of treatment.
U.S. Patient Assistance Program
Gilead is committed to ensuring that people with hepatitis C can access Sovaldi and has launched Support Path™ (www.MySupportPath.com) to provide assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. - See more at: http://hepatitiscnewdrugresearch.com/index.html#sthash.xblNW8ba.dpuf
Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?
Prescribing and patient information, FDA articles, videos and important updates
Simeprevir Approved In The United States
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
Johnson & Johnson's protease inhibitor OLYSIO (Simeprevir) is approved for the treatment of HCV genotype 1, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin.
Simeprevir was approved in Japan this past September , and in Canada on November 20th.
*Updated December 5
HCV Drug Olysio (simeprevir) - The New Kid On The Block
OLYSIO (Simeprevir) Cost? - Janssen has priced Olysio at a wholesale acquisition price of $22,120 per bottle of 28 capsules (150 mg capsules), which is an approximately one-month supply. That's roughly $66,360 for a three-month course.
Lessons Learned - An important lesson we learned from these drugs may serve as a reminder for future DDAs, that is, once telaprevir and boceprevir were used in larger groups of patients, or in "real-life" settings - outside clinical trials, new response rates and adverse effects began to emerge.
Simeprevir drug–drug interactions - Simeprevir has a list of medications that can cause drug–drug interactions Other medications can interfere with the way DDAs are metabolized. The drug–drug interactions can either increase drug concentrations which may cause toxicity and lead to side effects, or decrease drug concentrations leading to a loss of efficacy.
Off Label Use - Simeprevir and Sofosbuvir? - Paul Sax, Editor-in-Chief at NEJM Journal Watch wrote an article this past summer on the possibility of combining simeprevir and sofosbuvir with or without ribavirin, to create an off label interferon-free regimen....
J & J Patient Financial Assistance Program
Important Safety Information
OLYSIO (simeprevir) - Resistant Variant Q80K polymorphism
Olysio-simeprevir/Dosing & Uses, Drug Interactions, Adverse Effects
On November 22nd the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), supported Sovaldi® (sofosbuvir) for the Treatment of Chronic Hepatitis C
The CHMP opinion supports the approval of Sovaldi for the treatment of HCV in combination with other agents. The CHMP's recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union (EU).
For detailed information please download the FDA review package for sofosbuvir and simeprevir.
FDA Updates For Sofosbuvir
FDA Updates For Simeprevir
Quick Links - Hepatitis C Investigational Drugs
News, Research And Clinical Trials
See **Clinical Trials @ HCV Advocate For Enrollment Information
AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary
News and Research
ABT-450/r - ABT-267 - ABT-333-non- nucleoside
r = ritonavir
**Clinical Trials @ HCV Advocate-AbbVie
News and Research
**Clinical Trials @ HCV Advocate-Achillion
News and Research
Faldaprevir/ (BI 201335)
**Clinical Trials @ HCV Advocate-Boehringer Ingelheim
News and Research
GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir,
**Clinical Trials @ HCV Advocate-Bristol-Myers Squibb (BMS)
News and Research
GS-0938 and Sofosbuvir
**Clinical Trials @ HCV Advocate-Gilead
News and Research
**Clinical Trials @ HCV Advocate-Idenix
News and Research
**Clinical Trials @ HCV Advocate-Tibotec / Janssen
News and Research
**Clinical Trials @ HCV Advocate-Merck
News and Research
**ClinicalTrials.gov - Danoprevir
News and Research
**ClinicalTrials.gov - Miravirsen
News and Research
**Clinical Trials @ HCV Advocate-Vertex
To learn more about Hepatitis C virus clinical trials or to find out if a study is enrolling patients in your area, please click here.
ClinicalTrials.gov: updated in the last 30 days
- ► 2013 (926)
- ► 2012 (1293)
- What can new era of Hepatitis C antivirals offer b...
- Hepatitis C News For Friday April 20th
- Merck Executive Sees FDA OK, Launch Of Boceprevir ...
- New Video 2011/Hepatitis C Treatment W-Telaprevir ...
- FDA Panel Backs Approval Of Telaprevir For Hepatit...
- FDA May See Advantages for Telaprevir Over Bocepre...
- Hepatitis C Therapy; Adherence to Treatment and Qu...
- New Hepatitis C Drugs In The News; Telaprevir and ...
- FDA panel backs Merck/Boceprevir hepatitis drug
- Telaprevir April 28th View The "Live Webcast" From...
- "Yes" FDA advisory panel recommends approval of bo...
- Boceprevir "Live Feed" From The FDA Advisory Panel...
- Merck/Boceprevir: FDA Hep C Panel "Live Blog" From...
- Atwater Carey First Aid Kit Consumers Regarding Tr...
- Vertex will utilize AGA Digestive Health Outcomes ...
- Hepatitis C;Phase 3 trials recruiting to evaluate ...
- Video/Hearing about VA dental clinic-Five patients...
- FDA Staff Sees Only Minor Issues for Telaprevir
- Hepatitis C News; Boceprevir Wins Favorable FDA St...
- Hepatitis C News; Boceprevir(safety issues) and Te...
- First Patient Enrolled in Gore Early TIPS for Asci...
- Wednesday- Boceprevir Thursday-Telaprevir: Goes Be...
- Happy Easter
- Top 15 Least Contaminated Fruits, Vegetables
- 579 approved for medical marijuana in Arizona
- Treat Depression to Boost Diabetes Self-Care: Stud...
- Comparison of treatments for chronic fatigue syndr...
- New Orleans "Endoscopes Were Not Properly Steriliz...
- Is the Edmonton HCV/HIV Scenario Setting Us Back D...
- Hepatitis C; Idera Delays Initiation of Phase 2 C...
- Gut Bacteria Falls Into Three Major Types
- Antidepressants may not improve all symptoms of de...
- A randomized controlled trial of peginterferon alf...
- Depression May Complicate Hepatitis C Therapy
- "Post" Hepatitis C Treatment Problems/Symptoms : A...
- Walnuts: Healthy Nuts and You
- FDA Panel Is Set To Review Two New Hepatitis C Dru...
- Genetics of hepatitis C linked hepatocellular carc...
- Ohio panel wants more VA tests for clinic patients...
- HCV/HIV; The Risk Is Low For Edmonton surgical pat...
- Merck- Boceprevir, Vertex-Telaprevir Prep for Hep ...
- Positive Clinical Data of JX-594 in Combination W-...
- Water Frogs Update;Risk for Salmonella
- Hep C In The News;Menopause,Oysters,Antidepressant...
- Hepatitis C treatment among racial and ethnic grou...
- Hepatitis C News; European Gastroenterologists Wil...
- Fatty Liver Disease Can Lead to Heart Attack
- AIDS Prevention Pill Study Halted; No Benefit Seen...
- Hepatitis in Ambulatory Care: The Need for New Str...
- Ginseng doesn’t help patients with early diabetes
- Monday Hepatitis C In The News; HIV Vaccine As Dis...
- Hepatitis C: IL28B test Launced by AccuType® to ph...
- Is Type-2 diabetes an autoimmune disease?
- Prime-Boost Vaccine Against Hepatitis C: CInovio,T...
- Treating Hepatitis C: That Was Then, This is Now
- Drug-Related Adverse Events Soar, Linked to Pricey...
- Should Patients with Abnormal Liver Function Tests...
- Common drug linked to hepatitis
- The Hepatitis C Treatment Pipeline Report
- HCV New Drugs; Blog Updates
- Adverse Effects: Management of Hepatitis C Antivir...
- Stages in Chronic Hepatitis C: Blood Test and Fibr...
- Impact of radiation:Hepatitis virus infection on r...
- Review of liver injury associated with dietary sup...
- 47 percent of people 50 years old and over use her...
- Boceprevir, Telaprevir to Usher in New Era of Hepa...
- Hepatitis C; Highlighting Conatus' Drug CTS-1027
- Hepatitis E Virus infection in HIV-infected patien...
- Video-Chronic fatigue syndrome:Potential causes an...
- Community and personal risk factors for hepatitis ...
- Nationwide study finds US meat and poultry is wide...
- NBLCA Says Defunding Healthcare will Hurt HIV/AIDS...
- Hepatitis C; Understanding the Basic Metabolic Pro...
- Inflammation of the Liver
- HIV/AIDS-like symptoms; UNDIAGNOSED DEBILITATING I...
- Hep C and alcohol on liver-related morbidity and m...
- Hepatitis C: Greenwich doctor accused of insider t...
- Video/Physicians often recommend treatment options...
- HCC (liver cancer), diet, and metabolic factors
- Hepatocellular recurrence after orthotopic liver t...
- Fibroscan for assessing liver fibrosis: An accepta...
- Milk thistle for treatment of nonalcoholic fatty l...
- Hepatitis C News; Update On H&P Tainted Wipes
- VA patients, adults, now children at risk for cont...
- Hepatitis C News; Pediatric tampered vaccines also...
- Predicting sustained virological response in chron...
- New Compounds Show Promise Against Hepatitis C Inf...
- Hepatitis C: Why Am I So Tired ? Fatigue In HCV
- Hepatitis C News; PPI-437, PPI-668 AND PPI-833 ACT...
- Guideline for Treating Diabetic Nerve Pain Unveile...
- Doctors won't always take their own advice: study
- Study;Low carnitine levels linked to fatigue sever...
- Noninvasive tests may determine chronic hepatitis ...
- Patients taking antidepressants likely to stick wi...
- Hepatitis C Making The Monday News; New Technique ...
- The health halo effect: Don't judge a food by its ...
- Hepatitis C; How interferon-induced genes launch a...
- Hepatitis C: Sunday Mornings, My Computer and Coff...
- Boomer Health Hepatitis C isn’t only found in drug...
- New Zealand Trial PSI-7977 and RBV With and Witho...
- Tackling hepatitis C: a tale of two countries
- Avalanche of hepatitis C products on the way
- High-intensity ultrasound gets high marks for HCC ...
- ED ultrasound helpful but not definitive in diagno...
- Telaprevir Increases Second-Phase Hepatitis C Decl...
- New hepatitis C drugs pose many questions
- Updated April 8th; Digest Of Over 100 US Hepatitis...
- Hepatitis C Update Phase 2b ATOMIC Trial of PSI-79...
- Hepatitis C Update Phase III Trial of TMC435 Now R...
- Hepatitis C Making The News: April 8th
- RISK FACTORS FOR DEVELOPMENT OF HEPATOCELLULAR CAR...
- ASSESSMENT WITH MAINTENANCE INTERFERON IN PATIENTS...
- DOES SCREENING FOR HEPATITIS C RESULT IN EARLY DET...
- PROGRESS OF LIVER DISEASE IN HEPATITIS C VIRUS CAR...
- LONG-TERM FOLLOW UP OF PATIENTS WITH SPONTANEOUS C...
- SUBTYPE 1B DOES NOT CONFER A TREATMENT ADVANTAGE T...
- BASELINE SERUM HDL AND VITAMIN D LEVELS ARE STRONG...
- DIFFERENT PATTERN OF DECOMPENSATION IN ALCOHOLIC V...
- LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH...
- EASL;Session Title: Category 02b: Cirrhosis and it...
- Bay County Health Dept: Bacteria found in raw oyst...
- AP IMPACT: Synthetic drugs send thousands to ER "m...
- Hepatitis C "HALT-C" Increased mortality rates see...
- Surgeon who removed healthy organs only gets four ...
- Dried blood spots for HCV measurement among inject...
- Treatment For Liver Cancer – Study On The Outcome ...
- HCV News;Roche Joins in Spanish Research Cooperati...
- Hepatitis C; IL28B-Genotype Testing Now and in the...
- Can chronic hepatitis C resolve spontaneously?
- Acute pericarditis due to pegylated interferon alp...
- Video/ Walnuts May Be The Healthiest Nut
- Getting to the root of fatty liver disease
- 2011 EASL; Easy To Understand Summary of the inves...
- Hepatitis C In The News For April 5; Mericitabine ...
- Liver Cancer;PS-Targeting Antibody Significantly I...
- More On Tainted Wipes;U.S. marshals seize material...
- Transmission of Hepatitis B Virus from Blood Donor...
- Diabetes Increased risk liver cancer in men and wo...
- Issues Clinical Practice Guidelines for Management...
- Two VA dental clinic patients test positive for he...
- (RG7128) Slides/Data on all the New HCV drugs pres...
- EASL; Phase 2 Study of ABT-450/r for Treatment of ...
- Expensive new hepatitis c drugs may restrict use i...
- BI 201335; Positive Phase 2 results Boehringer Ing...
- Hepatitis C compound BI 201335 moves into Phase II...
- Non-alcoholic fatty liver disease will reach epide...
- HEPATOCELLULAR CARCINOMA ; THALIDOMIDE SHOWS EFFIC...
- Drug-resistant variants emerge in most patients wh...
- Bristol-Myers Interferon-Free Combo And 4-Drug Co...
- EASL; Hepatitis C "IMO-2125" in Treatment-Naïve Ge...
- New hepatitis c protease inhibitors from Dr. Joe G...
- New Video: Boceprevir research published in the Ne...
- Hepatitis C ; Telaprevir Helps in Prior HCV Tx Fai...
- Autologous Induced Pluripotent Stem Cells And Gene...
- Boceprevir; Four-Week Lead-In Response and IL28B S...
- Better Then SOC; Improvements in Viral Cure Rates ...
- EASL; INX-189 Positive Safety/Antiviral Data from ...
- EASL "VX-222 Plus Telaprevir,Peg/Riba" Interim Pha...
- Hepatitis C; HCC Have Risen Dramatically
- EASL "TMC435" Hepatitis C Phase 2b ASPIRE Study We...
- ▼ April 2011 (160)
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Prescribing Information for INCIVEK including the Medication Guide.
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
- (Sofosbuvir) now Sovaldi (2)
- 2012 -168 Pages Of HCV FAQs (1)
- a 2013 Conference ID Week (3)
- A 2013 Conference on Retroviruses and Opportunistic Infections (4)
- A Guide 2011-Management Of HCV (2)
- A Guide 2012-Guideline for Nonalcoholic Fatty Liver Disease (1)
- A-2012 EASL-AASLD Special Conference (2)
- A-2012 Update on the Diagnosis and Treatment of Hepatitis C (1)
- A-2012-New guidelines on the management of hepatocellular carcinoma (HCC). (1)
- A-2013 EASL Revised guidelines for management of HCV (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- a-DDW 2011 Meeting (11)
- a-DDW 2012 meeting (21)
- a-DDW 2013 meeting (23)
- A-EASL 2011 Summary (1)
- A-EASL 2012 (79)
- A-EASL 2012 - Guidelines on the Management of Chronic Hepatitis B (1)
- A-EASL 2012 Index (1)
- A-EASL 2012 Internet Symposium (2)
- A-EASL 2012 Summary Of The Meeting (1)
- a-EASL 2013 (51)
- A-EASL 2013 Summary Of The Meeting (1)
- a-EASL 2013-abstract search (1)
- A-List Of Unnecessary Medical Tests (1)
- A-New targets for antiviral therapy (100)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-63rd Annual Meeting (73)
- AASLD 2012-STC (1)
- AASLD 2013 (46)
- AASLD 2013 Summary-Symposium (2)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (2)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-267 (13)
- ABT-333-non- nucleoside (13)
- ABT-450 (11)
- ABT-450/r (25)
- ABT-450/r and ABT-072 (4)
- ABT-450/r plus ABT-333 (10)
- ABT-450/R/ ABT-267/ABT-333/ribavirin (5)
- Acetaminophen Safety (9)
- ACH-1625 (15)
- ACH-2684 (5)
- ACH-2928 (2)
- ACH-3102 (9)
- acute HCV (4)
- addiction (21)
- Adherence to therapy (13)
- alcohol consumption (17)
- alisporivir (4)
- ALS-2200 (3)
- ALS-2200 (VX-135) (13)
- ALS-2200 and ALS-2158 (3)
- ALS2158 (1)
- ANA598 (5)
- ANA598-setrobuvir (2)
- ANA773 (1)
- ANA958 (1)
- anemia (9)
- antidepressants (5)
- arthritis (5)
- ascites (9)
- Asunaprevir (4)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (14)
- Bavituximab (5)
- BCX5191 (2)
- Behind the Headlines (10)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (5)
- BI 201335 and BI 207127 (10)
- BI 207127 (7)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- Biopump (1)
- BioScience (2)
- biosimilars (6)
- BIT225 (2)
- BL-8020 (2)
- blood safety (3)
- blood scandal (3)
- bms-650032 (6)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (10)
- BMS-650032 and BMS-790052 (5)
- bms-790052 (18)
- bms-790052-declatasvir (10)
- BMS-986094-INX 189 halted (8)
- BMS-986094-INX 189 on hold (7)
- boceprevir (98)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (195)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (7)
- Caleco Pharma (1)
- Canada (3)
- cancer (15)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (5)
- CDC- World Hepatitis Day 2011 (1)
- CDC- World Hepatitis Day 2012 (4)
- CDC- World Hepatitis Day 2013 (2)
- children treating HCV (15)
- chronic disease (2)
- chronic fatigue (16)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (190)
- cirrhosis-complications (13)
- cirrhosis-Vibrio vulnificus-raw oysters (2)
- clinical trials (128)
- clinical trials-Pro-Con (4)
- coffee (31)
- Colloidal silver (2)
- colonoscopy (2)
- compensated cirrhosis (11)
- Complementary and Alternative Medicine (30)
- Counterfeit drugs (8)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (5)
- CTS-1027 (5)
- Cyclophilin Inhibitors (1)
- Daclatasvir (9)
- daclatasvir-peg/riba (4)
- Daclatasvir/Asunaprevir (7)
- daclatasvir/asunaprevir/BMS-791325 (5)
- Daily Consensus Interferon (1)
- Danoprevir (17)
- Danoprevir/Mericitabine (3)
- DEB025 (2)
- DEB025- alisporivir (4)
- decompensated cirrhosis (18)
- Dental (4)
- Depression (17)
- diabetes (106)
- diabetes-insulin resistance (8)
- Digestion (2)
- Direct-acting Antivirals (11)
- disease progression (13)
- donation (16)
- drug alerts (1)
- Drug Assistance Programs (5)
- Drug Resistance Test (1)
- drug shortages (1)
- dry eye (3)
- dyspepsia (1)
- EASL (59)
- Economic Burden HCV (2)
- ELAD® Bioartificial Liver (1)
- encephalopathy (28)
- endoscopy (1)
- Epidemic HCV (10)
- Epogen (4)
- ESLD (1)
- faldaprevir (20)
- faldaprevir w-PPI-668/deleobuvir(BI207127) (3)
- faldaprevir/ (BI 201335) (24)
- faldaprevir/BI 207127 (2)
- faldaprevir/DELEOBUVIR (4)
- fatigue (8)
- Fatigue-Cognitive Function-Sleep Quality (3)
- Fatty Liver (126)
- Fatty Liver-RP103 (1)
- FDA (83)
- fibromyalgia (9)
- Fluvastatin (3)
- Foodborne illness (18)
- G7128 (1)
- gallbladder (1)
- gallstones (10)
- gastritis (1)
- Gastroenterologist (2)
- geno1 (104)
- geno2 (57)
- geno3 (65)
- geno4 (32)
- geno5 (6)
- geno6 (11)
- genotype test (1)
- genotypes;All (14)
- green tea (2)
- GS-0938 and Sofosbuvir (1)
- GS-5885 (4)
- GS-7977 now Sofosbuvir (124)
- GS-7977 now Sofosbuvir and simeprevir (TMC435) (8)
- GS-7977 now sofosbuvir / GS-5885 now ledipasvir (20)
- GS-7977 now Sofosbuvir off label use (1)
- GS-7977 now Sofosbuvir Plus Riba (3)
- GS-7977 now Sofosbuvir-FDA Review (12)
- GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir (11)
- GS-7977 Plus Peg/Riba (3)
- GS-9190 (7)
- GS-9256 (6)
- GS-9451 (2)
- GSK2336805 (4)
- Gut Bacteria (1)
- H pylori (1)
- HALL OF SHAME (44)
- HALT-C (8)
- hav (8)
- hav vaccine (2)
- hbv (113)
- hbv vaccine (4)
- HCV Australia (7)
- hcv abstracts (236)
- HCV agents/drug interactions (1)
- HCV Awareness (84)
- HCV Awareness-screening strategies (36)
- HCV Baby Boomers (41)
- HCV cardiovascular disease (1)
- HCV diet (8)
- HCV Forum (1)
- HCV generics (1)
- HCV hypertension (1)
- HCV natural compounds (1)
- HCV neurocognitive function (1)
- HCV News (1708)
- HCV News-monthly rewind (1)
- HCV News-weekly rewind (20)
- HCV pregnancy (9)
- HCV Protease Inhibitors in Active Drug Users (1)
- HCV replication (3)
- HCV research (97)
- HCV Self-management (1)
- HCV symptoms (3)
- HCV tests (25)
- HCV tests-endoscope (1)
- HCV transmission FAQ (1)
- HCV Vaccine (26)
- HCV vaccine GI-5005 (7)
- HCV Vaccine-TG4040 (MVA-HCV) (2)
- HCV Worldwide (35)
- HCV Worldwide Asia Australia Egypt (2)
- HCV Worldwide-Egypt (1)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-autoimmune diseases (1)
- HCV-Breast Cancer (1)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (12)
- HCV-Education (76)
- HCV-elderly (5)
- HCV-Insulin resistance (13)
- HCV-Statins (8)
- HCV-TARGET (1)
- HCV/HBV/HIV special populations (1)
- Health Reform (3)
- Health Reform-Insurance (4)
- Healthy you (47)
- hemochromatosis (1)
- HepaFat™ (1)
- Hepatitis-related Renal Disease (1)
- hepatocyte cell transplantation (1)
- hepatologist (2)
- hepatoSys Virtual Liver Network (1)
- herb (36)
- herb-kava (2)
- HEV (4)
- History of HCV (4)
- HIV (120)
- HIV-children (3)
- hiv/hbv-coinfection (1)
- HIV/HCV (80)
- hot topic (9)
- HTAs-host-targeting agents (1)
- human genome (6)
- human interferon alpha lozenges (2)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (21)
- IDX184-Discontinued (1)
- IDX19368-Discontinued (1)
- IDX19368-hold (2)
- IDX20963/FDA Request More Data (2)
- IDX719 (9)
- if I had.. (9)
- IFNL 4 (1)
- IL-7(CYT 107) (1)
- IL28B (64)
- IL28B Test (2)
- immune system (10)
- IMO-2125 (6)
- Inflammation (3)
- Inflammation Liver (2)
- Inflammatory Bowel Disease (1)
- INFRADURE Biopump (1)
- Inspirational (28)
- Insurance (1)
- Insurance medicare (1)
- interferon (5)
- Interferon Free Combinations (151)
- Interferon lambdas (1)
- Investment News HCV Drugs (22)
- INX 189 (13)
- IP-10 (1)
- ITX-5061 (1)
- IV drug use (1)
- Joint pain (1)
- Just for fun (5)
- JX594/TG6006 (2)
- Lambda (7)
- ledipasvir (GS-5885) (5)
- Lichen Planus (5)
- List Peer-Reviewed Journals (2)
- Liver Abscess (2)
- liver biopsy (14)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (260)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (77)
- liver cancer treatment-radiofrequency ablation (RFA) (2)
- Liver Cancer-HEAT Study of ThermoDox(R) (3)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (4)
- Liver Cysts (1)
- liver disease (26)
- Liver Fibrosis (114)
- liver function tests (13)
- liver health (82)
- Liver Injury Dietary Supplements (11)
- Liver Injury-Shark liver oil (1)
- Liver Pain (6)
- liver surgery (3)
- liver/anatomy (1)
- Locteron/interferon (3)
- lymphoma (3)
- M11-602 (1)
- marijuana (30)
- marijuana-based prescription drug (1)
- MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188) (1)
- Mediterranean diet (2)
- Men and HCV (4)
- microspheres (3)
- Milk thistle (24)
- Miracle Mineral Solution-MMS (1)
- Miravirsen (9)
- miRNAs (1)
- MK-5172 (15)
- MK-5172/peg/riba (1)
- MK-5172/Vaniprevir(MK-7009) (1)
- MK-7009 (4)
- MK-8742 (4)
- monoclonal antibody GS-6624 (1)
- Morbidity-SVR (7)
- Mortality (16)
- nanoparticles (3)
- Nanotechnology (3)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (5)
- new drugs (5)
- new hcv drugs (55)
- newly diagnosed (10)
- newsletters (53)
- Nitazoxanide (2)
- noni juice (1)
- noninvasive tests for fibrosis (42)
- nonresponders (9)
- NS5A inhibitor (2)
- NSAID (7)
- nucleoside inhibitors (1)
- null responders (10)
- occult hepatitis C virus infection (1)
- Off Topic (34)
- online pharmacy (1)
- Oral interferon (1)
- organ harvesting (11)
- organ trafficking (5)
- organ trafficking- U.S (1)
- organ-imported tainted tissue (1)
- Origin Of Hepatitis (2)
- Other Conditions Related To HCV (51)
- Other Conditions Related To HCV-Vasculitis (5)
- Other Health News (121)
- OTHER INFECTIOUS DISEASE (20)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (3)
- Pegasys (10)
- Peginterferon (77)
- PegIntron (4)
- Peripheral Neuropathy (2)
- PF-05095808 (1)
- Pharmaceuticals (146)
- Pink eye-Sty-and other eye conditions (1)
- platelets (4)
- polymerase inhibitor (16)
- Porphyria Cutanea Tarda (PCT) (2)
- Post Treatment Symptoms (1)
- PPI-383 (1)
- PPI-461 (3)
- PPI-668 (3)
- primary biliary cirrhosis (PBS) (1)
- probiotics (2)
- procrit (4)
- prognostic test:response to therapy (1)
- promacta (1)
- prostate cancer (1)
- protease inhibitor (33)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (24)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (3)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Q80K polymorphism (1)
- Quackery (10)
- Questions About HCV (4)
- rash (10)
- recall (25)
- regeneration (6)
- regenerative Medicine (17)
- relapse (8)
- resistance to protease inhibitors (17)
- response-guided therapy (4)
- RG7128 (9)
- ribavirin (27)
- Ritonavir (1)
- rituximab (2)
- salt (5)
- SB 9200 (1)
- scientists grow human livers in laboratory (7)
- SCY-635 (5)
- SCY-641 (1)
- Seasonal Flu Vaccine (10)
- selenium (2)
- setrobuvir (1)
- side effects (71)
- side effects-direct-acting antivirals (19)
- side effects-eyes (8)
- side effects-telaprevir (4)
- silibinin (4)
- silymarin (4)
- Simeprevir (42)
- Simeprevir now Olysio (11)
- Simeprevir now Olysio FDA Approved (5)
- Simeprevir off label use (1)
- Simeprevir/Samatasvir (IDX719) (1)
- Simeprevir/TMC647055/ Samatasvir (IDX719 (1)
- SIR-Spheres microspheres (3)
- Small fiber neuropathy (2)
- sofosbuvir and ABT-450 (1)
- Sorafenib (6)
- sovaprevir (6)
- Sovaprevir (Formerly ACH-1625) (7)
- Sovaprevir/ACH-3102 (2)
- sphincter of Oddi (3)
- spleen (6)
- SPONTANEOUS CLEARANCE (13)
- Standardization of Terminology of Virological Response (1)
- Starting HCV Treatment (75)
- STAT-C (3)
- stem cell lawsuit (2)
- stem cell tourism (7)
- stem cell-diabetes (1)
- stem cells (82)
- stem cells-pluripotent (2)
- stem-cell-derived liver tissue model (1)
- stigma (1)
- supplements (22)
- support (48)
- support-hotline (5)
- Surgery in liver disease (3)
- svr (81)
- svr durability (4)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- SVR24-SVR12-SVR4 (9)
- Tattoos (2)
- telaprevir (125)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (20)
- telaprevir-incivek (236)
- telaprevir-incivek-Cost (3)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (2)
- Thalidomide (1)
- The natural history of hepatitis C (3)
- TheraSphere (2)
- Thrombocytopenia (4)
- Thrombocytopenia-Promacta (1)
- thrombosis (3)
- thyroid (11)
- Timeline Hepatiits (1)
- Timeline Hepatitis (1)
- TMC435 (26)
- TMC435 (Simeprevir) (36)
- TMC435-BMS-790052 (3)
- TMC647055 (3)
- TMC647055 and IDX719 (1)
- TMC649128 (4)
- toxicity (28)
- transmission (72)
- Transmission clinical setting (93)
- Transmission clinical setting-Government Report 2012 (1)
- Transmission of HCV Through Transplanted Organs (2)
- transmission-needlestick (3)
- transplant (182)
- transplant tourism (7)
- Transplant- Telaprevir/Boceprevir (3)
- transplant-certican (1)
- Transplant-GS-7977 now Sofosbuvir (1)
- transplant-MELD (8)
- Triad Prep Pads (16)
- TT-034 (1)
- tylenol (17)
- upper abdominal pain (2)
- varices (14)
- video (269)
- viral load (11)
- Virtual Liver (1)
- virus research (3)
- vitamin A (6)
- vitamin B12 (3)
- vitamin D (40)
- vitamin E (7)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (11)
- weekend reading (53)
- wellness (52)
- women (13)
- Xifaxan (1)
- XIX International AIDS Conference (4)
- zalbin (1)
- zinc (2)
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new improved hepatitis C drugs. As once a hepatitis C patient myself (I successfully treated the virus with standard HCV therapy in 2000) I understand the difficult decisions and overwhelming fear that ensues after being diagnosed with this serious and life-changing disease. This blog serves as a starting point for information on the rapidly evolving number of new agents in development to treat hepatitis C. Tina